• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Imagion Biosystems raises $9m with Aussie IPO

Imagion Biosystems raises $9m with Aussie IPO

June 22, 2017 By Brad Perriello

Imagion BiosystemsImagion Biosystems (ASX:IBX) said today that it raised $9.1 million (A$12 million) in an initial public offering on the Australian stock exchange for its MagSense cancer-tagging nanoparticles.

The 15.1¢-per-share (A20¢) flotation of 60 million shares is earmarked for 1st-in-human trials, expected during the 2nd half of 2018, the Albuquerque-based company said.

The MagSense nanoparticles have a 25nm iron oxide core and a specialized polymer coating and are designed to work with tumor-targeting biomarkers to attach themselves to cancer cells. Because they behave differently when bound to a cell antibody than when in free circulation, according to Imagion’s website.

“The different magnetic fields produced results in high detection specificity between attached and unattached nanoparticles. In the detection of cancer cells, superparamagnetic relaxometry has been shown to be several orders of magnitude more sensitive than conventional imaging methods,” according to the site.

Imagion is focused on HER2+ breast, ovarian and prostate cancers, which it claims represent an addressable market of $2 billion; the company said it expects to pursue the technology against other forms of the disease.

“The MagSense technology is 1,000 times more sensitive than current imaging methods, yet comes at a lower cost than conventional imaging, in addition to providing a non-invasive alternative to frequently used procedures,” CEO Robert Proulx said in prepared remarks. “The potential of the MagSense technology is evidenced by the incredibly strong board we have been able to attract which includes highly visible and respected professionals. MagSense addresses an important and very large unmet medical need that could dramatically improve outcomes for millions of patients, and we have an outstanding opportunity to create significant shareholder value by developing and commercializing the technology.”

($1 = A$1.32541)

Filed Under: Diagnostics, Funding Roundup, Initial Public Offering (IPO), Oncology, Wall Street Beat Tagged With: imagionbiosystems

More recent news

  • Preceptis Medical has a new CEO as it advances ear tube tech
  • FDA clears first over-the-counter cuffless blood pressure monitor
  • Mendaera wins FDA clearance for robotic needle placement
  • Johnson & Johnson seeks to have $442 million antitrust verdict tossed out
  • Former Masimo COO is joining BD to run Connected Care

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy